JAMA Oncol: Efficacy and safety of Pembrolizumab combined with concurrent chemoradiotherapy (cCRT) in the treatment of unresectable stage III NSCLC: KEYNOTE-799.

Approximately 25% of non-small cell lung cancer ( NSCLC ) are diagnosed as stage III patients, most of which are unresectable

Approximately 25% of non-small cell lung cancer ( NSCLC ) are diagnosed as stage III patients, most of which are unresectable

KEYNOTE-799 is a non-random, open-label Phase II study conducted in 52 research centers in 10 countries

KEYNOTE-799 is a non-random, open-label Phase II study conducted in 52 research centers in 10 countries

research summary

The ORR of cohort A patients was 70.

The ORR of cohort A patients was 70.

Two-queue ORR

The duration of remission (DOR) of the two cohorts was not reached

The duration of remission (DOR) of the two cohorts was not reached

Duration of Response (DOR) for the two cohorts

Treatment-related adverse events (AE), the incidence of cohort A and B were 93.

Treatment-related adverse events (AE), the incidence of cohort A and B were 93.

 Adverse events of treatment in two cohorts

In summary, Pembrolizumab combined with concurrent chemotherapy and radiotherapy (cCRT) is a feasible strategy for the treatment of unresectable stage III NSCLC with controllable toxicity

In summary, Pembrolizumab combined with concurrent chemotherapy and radiotherapy (cCRT) is a feasible strategy for the treatment of unresectable stage III NSCLC with controllable toxicity

Original source:

Salma K Jabbour, Ki Hyeong Lee, Nikolaj Frost, et al.
Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial.
JAMA Oncol.
2021 Jun 4.
doi: 10.
1001/jamaoncol.
2021.
2301.
Online ahead of print.

Salma K Jabbour, Ki Hyeong Lee, Nikolaj Frost, et al.
Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial.
JAMA Oncol.
2021 Jun 4.
doi: 10.
1001/jamaoncol.
2021.
2301.
Online ahead of print.


Leave a message here